Using Oracle's Empirica Topics to Document Your Signal Management Process

July 26, 2013

Rodney Lemery, MPH, PhD
Vice President, Safety and Pharmacovigilance BioPharm Systems, Inc.

PREVIOUS PREVIOUS

NEXT NEXT

Agenda

Signal Management using Oracle Empirica Products

Detection
Use of e-Signal for data mining

Prioritization Evaluation

PREVIOUS

NEXT

Signal Management

The process of identifying, prioritizing and evaluating determined signals in a data population

PREVIOUS

NEXT

Current Regulatory Environment

As of July 2, 2012, the EMA has required among other things
All validation, prioritisation, assessment, timelines, decisions, actions, plans, reporting as well as all other key steps should be recorded and tracked systematically. Tracking systems should be used for documentation and should also include signals, for which the validation process conducted was not suggestive of a new potentially causal association, or a new aspect of a known association. All records need to be archived (EMA, 2012).

In June of 2002, the US Congress reauthorized (for a second time) the Prescription Drug User Fee Act (PDUFA III)
Specifically, FDA issued three concept papers. Each paper focused on one aspect of risk management, including
o (1) conducting premarketing risk assessment o (2) developing and implementing risk minimization tools o (3) performing post marketing pharmacovigilance and pharmacoepidemiologic assessments. (FDA, 2005)
PREVIOUS NEXT

What the Industry Seeks

A systematic approach to signal management
Ability to identify potential issues in clinical and postmarketing data Standard prioritization questions Standard evaluation methods to feed risk management Pre-defined workflow for these processes

A system to collect and track this approach

Standard system to document the identification, prioritization and evaluation of signals Capability to report this process for audit answering and justification or risk methods (document due diligence)
PREVIOUS NEXT

Empirica Topics Workflow Example

PREVIOUS

NEXT

PREVIOUS

NEXT

Actions can be created and assigned to other users in the company

In this example, an action to review the case series is assigned

PREVIOUS

NEXT

Signals prioritized as High or Medium are moved into the Signal Evaluation workflow step for further investigation and signal workup

PREVIOUS

NEXT

Additional external documentation can also be attached to the topic to support the prioritization of the signal

PREVIOUS

NEXT

Using e-Signal, we can drill down into the case series that makes up the signal of interest

The case series can be attached to the topic of interest for historical identification
PREVIOUS NEXT

Additional external documentati on can also be attached to the topic to support the evaluation of the signal

PREVIOUS

NEXT

Using the default abilities of e-Topics, we can run reports documenting our signal management process at the request of a regulatory authority or equivalent

PREVIOUS

NEXT

Complete auditing of the topic case

PREVIOUS

NEXT

Summary
Using existing literature and Empirica Suite can be configured to provide a systematic method for signal management in a single solution that accomplishes the following: Ability to identify potential issues in clinical and post-marketing data Standard prioritization questions Standard evaluation methods to feed risk management Pre-defined workflow for these processes Capability to report this process for audit answering and justification or risk methods (document due diligence)

PREVIOUS

NEXT

References

Bennett Levitan, B., Yee, C. L., Russo,L., Bayney, R., Thomas, A. P. and Klincewicz, S. L.. (2008). A Model for Decision Support in Signal Triage. Drug Safety. 31 (9), pp. 727-735 Council for International Organizations of Medical Sciences (CIOMS). (2010). Practical Aspects of Signal Detection in Pharmacovigilance. Report of CIOMS Working Group VIII, Geneva . Heeley E, Waller P, and Moseley J. (2005). Testing and implementing signal impact analysis in a regulatory setting: results of a pilot study. Drug Safety 28 (10), pp. 901-6 Waller P, Heeley E, and Moseley J. (2005). Impact analysis of signals detected from spontaneous adverse drug reaction reporting. Drug Safety 28 (1), pp. 843-50 Waller P, Lee E. (1999). Responding to drug safety issues. Pharmacoepidemiology and Drug Safety 8 (7), pp. 535-52 Waller, P. (2010). An Introduction to Pharmacovigilance. Wiley-Blackwell. Oxford, UK

PREVIOUS

NEXT

Questions & Answers

Rodney L. Lemery MPH, PhD Vice Pres. Safety and PV

2000 Alameda de las Pulgas Suite 154 San Mateo, CA 94403-1270 www.biopharm.com Tel (650) 292-5310 Fax (650) 292-5301 rlemery@biopharm.com

PREVIOUS

NEXT